Premium
Pharmacogenetics of morphine: Potential implications in sickle cell disease
Author(s) -
Darbari Deepika S.,
Minniti Caterina P.,
Rana Sohail,
van den Anker John
Publication year - 2008
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.21027
Subject(s) - pharmacogenetics , morphine , medicine , opioid , disease , pharmacodynamics , pharmacology , methadone , ugt2b7 , pharmacokinetics , bioinformatics , genotype , gene , biology , receptor , genetics , glucuronidation , in vitro , microsome
Morphine is frequently used to treat painful episodes associated with sickle cell disease (SCD) but may fail to provide adequate analgesia in many patients. This concise review focuses on unique disease related changes in physiologic variables associated with SCD that impacts pharmacokinetics and pharmacodynamics of morphine and may contribute to the variability in analgesia. Emerging evidence suggests that the allelic variants in the genes involving the opioid (UGT2B7, OPRM1, and ABCB1 genes) and nonopioid system (COMT gene) can alter the efficacy of morphine. Am. J. Hematol., 2008. © 2007 Wiley‐Liss, Inc.